Caris Life Sciences announces collaborative new research on TET2

Caris Life Sciences (CAI) announced collaborative new research identifying TET2 clonal hematopoiesis, or CH, as a promising biomarker for improved response to immune checkpoint inhibitor, or ICI, therapy in patients with solid tumors. The study titled, ‘TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors,’ was led by Padmanee Sharma, at the James P. Allison Institute at The University of Texas MD Anderson Cancer Center and published in Cancer Cell. The study’s purpose was to investigate how immune cells carrying CH-derived TET2 mutations influence solid tumor immunology and respond to ICI therapy. Dr. Sharma and Shelley Herbrich, Ph.D., postdoctoral fellow in Dr. Sharma’s lab, explored the underlying mechanisms using TET2-mutant laboratory models, which revealed how these mutations shape immune dynamics within the tumor microenvironment. To validate the clinical relevance of these findings, the study leveraged Caris Life Sciences’ extensive clinico-genomic database, analyzing outcomes in a real-world cohort of nearly 36,000 patients with non-small cell lung cancer and over 25,000 colorectal cancer patients.